Accro Bioscience
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Accro Bioscience to Present Phase II Data of AC-201 for Plaque Psoriasis at the European Academy of Dermatology & Venereology Congress 2025 in Paris 2025-09-04 20:24
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis 2025-05-21 08:50
Accropeutics Secured $12 Million in Series B Plus Financing 2025-03-14 16:23
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101 2025-02-13 18:53
Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101 2024-12-13 12:57
TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I 2023-05-25 09:51
1